APEX1 and non-small cell lung carcinoma: A Phase II trial (NCT00540722) added gossypol to cisplatin/docetaxel in NSCLC patients with high APE1 tumors, but it did not significantly improve outcomes (though there was a nonsignificant trend toward longer survival) [168].